Ubrogepant: First Approval-Reference-Cited by-同舟云学术

Ubrogepant: First Approval

Published:2020-02 Issue:3 Volume:80 Page:323-328
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Scott Lesley J.

Abstract

AbstractUbrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults. This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-020-01264-5.pdf

Reference25 articles.

1. Holland PR, Goadsby PJ. Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics. 2018;15(2):304–12.

2. Chan C, Goadsby PJ. Recent advances in pharmacotherapy for episodic migraine. CNS Drugs. 2019;33(11):1053–71.

3. Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–50.

4. Allergan, Merck. Allergan enters into licensing agreement with Merck to obtain exclusive worldwide rights to CGRP migraine development program [media release]. 7 Jul 2015.

5. US Food & Drug Administration. FDA approves new treatment for adults with migraine [media release]. 23 Dec 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of Ubrogepant in Healthy Japanese and White Adults;Clinical Pharmacology in Drug Development;2024-01-23

2. Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States;Patient Preference and Adherence;2023-12

3. Supporting the Young Adulthood Transitions in Women With Migraine;Nursing for Women's Health;2023-12

4. Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review;Expert Opinion on Drug Metabolism & Toxicology;2023-11-15

5. A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine;Cureus;2023-11-02